ARCT-032
Phase 2Biologic
ARCT-032 is one of 41 biologic programs targeting Cystic Fibrosis. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
105 competitors in Cystic Fibrosis
#DrugCompanyPhaseTrials
1Ibsrela
AArdelyx
Phase 3
HSK31858
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Myambutol
VVA Greater Los Angeles Healthcare System
Phase 2
Tygacil
PPrism Pharmaceuticals
Phase 2
ELX/TEZ/IVA
Vertex PharmaceuticalsPhase 3
Trikafta
NNottingham University Hospitals NHS Trust
Phase 3
VNZ/TEZ/D-IVA
Vertex PharmaceuticalsPhase 3
VX-121/TEZ/D-IVA
Vertex PharmaceuticalsPhase 3
Verapamil Hydrochloride
Mylan Pharmaceuticals IncPhase 3
Hyperpolarized Xenon-129
TThunder Bay Regional Health Research Institute
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ARCT-032. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- AArcturus Therapeutics, Inc.